Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD
Sano M, Cummings J, Feldman H, Hansson O, van der Flier W, Bardtrum L, Jeppesen R, Johannsen P, LĂ©on T, Hansen C, Scheltens P. Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD. Alzheimer's & Dementia 2024, 20: e088735. PMCID: PMC11713595, DOI: 10.1002/alz.088735.Peer-Reviewed Original ResearchMini-Mental State ExaminationAmyloid positivityStrategic infarctsMild AD dementiaRepeatable BatteryPsychiatric disordersCognitive Assessment scoreMild cognitive impairment due to ADInclusion of participantsCognitive impairment due to ADCognitive scoresMini-MentalState ExaminationCDR scoreNeurological disordersScreening failureDisordersEvidence of neurologic disordersAD dementiaScreening failure rateSmall vessel pathologyEvokedScoresCentral nervous systemHierarchical screening procedure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply